News | Magnetic Resonance Imaging (MRI) | September 14, 2018

Philips Launches Ingenia Ambition X 1.5T MR

Ingenia Ambition X combines fully sealed BlueSeal magnet technology and workflow innovations for a step-change in productivity

Philips Launches Ingenia Ambition X 1.5T MR

September 14, 2018 — Philips announced the launch of the Ingenia Ambition X 1.5T magnetic resonance imaging (MRI) scanner. It is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter and simpler path to enabling a confident diagnosis. The first commercial installation of the Ingenia Ambition X was recently completed at Spital Uster Hospital, a major provider of extended primary healthcare in the canton of Zurich, Switzerland. The Ingenia Ambition X is CE marked and has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

In radiology, meeting the need for high productivity and an improved patient experience while ensuring excellence in imaging can be daunting. The perception is often that MR represents a trade-off between productivity and image quality. The Ingenia Ambition X provides what Philips calls leading-edge MRI capabilities while helping to increase overall productivity, combining its BlueSeal magnet with innovations that can help reduce downtime, enable single-operator workflow and speed up exam times by up to 50 percent.

Incorporating Philips' BlueSeal fully-sealed magnet, the Ingenia Ambition X is the world's first MR system to enable helium-free operations [3], reducing the chance of potentially lengthy and costly disruptions, and virtually eliminating dependency on a commodity with an unpredictable supply. The fully-sealed system does not require a vent pipe and is around 900 kg lighter than its predecessor, significantly reducing the siting challenges presented by conventional magnets and lowering construction costs.

"We are very proud to be the first hospital in the world to offer this new cutting-edge, resource-friendly MRI technology to our patients," said Andreas Steinauer, M.D., chief radiologist at Spital Uster Hospital, Switzerland. "With the new Philips Ingenia Ambition X our patients can have the best of two worlds: leading MRI technology with a smaller footprint. This new leaner platform will allow more sites to deliver advanced MRI technology to their patients, helping to improve patient care."

The Ingenia Ambition X includes a range of new features that combine to deliver a step-change in productivity, according to Philips. With Philips' EasySwitch solution, the BlueSeal's magnetic field can be easily turned off if an item becomes stuck in the bore. Once the problem is resolved, an in-house or Philips technician can initiate an automated ramp-up to bring the magnet back to field, minimizing operational downtime. A conventional MR can require two staff to manage daily operations. The Ingenia Ambition X combines guided patient setup and Adaptive Intelligence-driven SmartExam analytics for automatic planning, scanning and processing. This frees up time to enable a single operator to manage the full scan from the patient's side with just a single touch of a button.

Philips Compressed SENSE is an advanced acceleration application that reduces exam times by up to 50 percent. In addition, Philips VitalEye is a unique approach to detecting patient physiology and breathing movement. VitalEye technology and algorithms intelligently extract signs of breathing – allowing routine exam set-up time to occur in less than a minute, even for less experienced operators. Together, these innovations help to standardize and speed up workflow, allowing clinicians to focus on the patient.

Read the article "Miami Cardiac and Vascular Institute Implements Philips Ingenia Ambition X 1.5T MRI"

For more information: www.usa.philips.com/healthcare

Related Content

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large

This illustration show the complexity of the data obtained from one single patient with moderate/severe traumatic brain injury. Different imaging approaches and techniques have their own unique sensitivity in assessing different aspects of neuroanatomy and neuropathology. What can be seen on images also changes with time since injury. Data from comprehensive clinical and functional assessments using a range of other tools is also important for evaluating patient outcome. Through data harmonization and large-scale analyses of data combined across multiple research sites, the ENIGMA Brain Injury will develop and test methods and procedures for making sense of the complexity in this data. Images courtesy of Olsen et al., Brain Imaging and Behavior, 2020

News | Magnetic Resonance Imaging (MRI) | October 23, 2020
October 23, 2020 — Trau...
A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe.

A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | October 22, 2020
October 22, 2020 — According to an open-...
The fMRI hyperscanning environment.

(A) The fMRI hyperscanning environment. The clinician (1) and patient (2) were positioned in two different 3T MRI scanners. An audio-video link enabled online communication between the two scanners (3), and video images were used to extract frame-by-frame facial expression metrics. During simultaneous acquisition of blood oxygen level–dependent (BOLD)–fMRI data, the clinician used a button box (4) to apply electroacupuncture (EA) treatment (real/sham, double-blind) to the patient (5) to alleviate evoked pressure pain to the leg (6; Hokanson cuff inflation). Pain and affect related to the treatment were rated after each trial. (B) Study overview. After an initial behavioral visit, each individual participated in a Clinical-Interaction (hyperscan preceded by a clinical intake) and No-Interaction condition (hyperscan without a preceding intake), in a counterbalanced order, with two different partners. (C) Experimental protocol. Each hyperscan was composed of 12 repeated trials (four verum EA, four sham EA, and four no treatment) in a pseudo-randomized order. After a resting period (far left), both participants were shown a visual cue to indicate whether the next pain stimulus would be treated (green frame) or not treated (red frame) by the clinician. These cues prompted clinicians prepare to either apply or not apply treatment while evoking corresponding anticipation for the patient. Following the anticipation cue, moderately painful pressure pain was applied to the patient’s left leg, while the clinician applied or did not apply treatment, respectively. After another resting period, participants rated pain (patients), vicarious pain (clinicians), and affect (both) using a visual analog scale (VAS).

News | Clinical Trials | October 22, 2020
October 22, 2020 — The potential impact of the patient-clinician relationship on a patient's response to treatment is
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...
Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA)

Lesion was originally reported as indeterminate enhancing mass, and outside report recommended biopsy. Classic features of benign hemangioma are shown. Error was attributed to faulty reasoning. A, Axial MR image obtained 5 minutes after contrast agent administration shows peripheral nodular discontinuous enhancement. B, Axial MR image obtained 10 minutes after contrast agent administration shows centripetal progression of enhancement (arrow). C, Axial fast imaging employing steady-state acquisition (FIESTA) MR image shows lesion is homogeneously hyperintense compared with liver parenchyma. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | October 21, 2020
October 21, 2020 — According to an artic...
According to an inquest, a man with a heart disorder and chest pain died two days after a doctor viewed the wrong scan and sent him home
News | Computed Tomography (CT) | October 21, 2020
October 21, 2020 — The BBC News
Flowchart of patient inclusion and exclusion.

Figure 1. Flowchart of patient inclusion and exclusion.

News | Coronavirus (COVID-19) | October 20, 2020
October 20, 2020 — A new multi-institutional study published in the journal ...
Rensselaer, First-Imaging, and GE Global researchers develop a deep neural network to perform nearly as well as more complex dual-energy CT imaging technology
News | Computed Tomography (CT) | October 20, 2020
October 20, 2020 — Bioimaging technologies are the eyes that allow doctors to see inside the body in order to diagnos
Ezra, a NY-based startup transforming early cancer screening using magnetic resonance imaging (MRI), announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first prostate AI to be cleared by the FDA.
News | Artificial Intelligence | October 20, 2020
October 20, 2020 — Ezra, a NY-based startup transforming early cancer screening using...